Characterization and validation of *Entamoeba histolytica* pantothenate kinase as a novel anti-amebic drug target

**Journal**
International Journal for Parasitology: Drugs and Drug Resistance

**Volume**
8

**Number**
1

**Page Range**
125-136

**Year**
2018

(C) 2018 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY license

URL
http://hdl.handle.net/2241/00151709

doi: 10.1016/j.ijpddr.2018.02.004

| 著者別名 | 橋本 哲男・松田 真秀 |
| --- | --- |
| タイトル | Characterization and validation of *Entamoeba histolytica* pantothenate kinase as a novel anti-amebic drug target |
| 原文 | 研究の目的は、アメバのパントテン酸キナーゼを新規抗アメバ薬のターゲットとして評価することです。

**Copyright**

Creative Commons Attribution License (CC BY)
Characterization and validation of Entamoeba histolytica pantothenate kinase as a novel anti-amebic drug target

Arif Nurkanto, Ghulam Jeelani, Takehiro Yamamoto, Yoshiko Naito, Takako Hishiki, Mihoko Mori, Makoto Suematsu, Kazuo Shiomif, Tetsuo Hashimotoa, Tomoyoshi Nozakic,1

a Graduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Japan
b Department of Parasitology, National Institute of Infectious Diseases (NIID), Tokyo, Japan
c Department of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo, Japan
d Research Center for Biology, Indonesia Institute of Sciences (LIPI), Cibinong, Indonesia
e Department of Biochemistry, School of Medicine, Keio University, Tokyo, Japan
f Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan
g Clinical and Translational Research Center, Keio University School of Medicine, Japan

ARTICLE INFO

Keywords:
Entamoeba histolytica
Amebiasis
Coenzyme A
Pantothenate kinase
Gene silencing
Drug development

ABSTRACT

The Coenzyme A (CoA), as a cofactor involved in > 100 metabolic reactions, is essential to the basic biochemistry of life. Here, we investigated the CoA biosynthetic pathway of Entamoeba histolytica (E. histolytica), an enteric protozoan parasite responsible for human amebiasis. We identified four key enzymes involved in the CoA pathway: pantothenate kinase (PanK, EC 2.7.1.33), bifunctional phosphopantothenate-cysteine ligase/decarboxylase (PPCS-PPCDC), phosphopantetheine adenyltransferase (PPAT) and dephospho-CoA kinase (DPCK). Cytosolic enzyme PanK was selected for further biochemical, genetic, and phylogenetic characterization. Since E. histolytica PanK (EhPanK) is physiologically important and sufficiently divergent from its human orthologs, this enzyme represents an attractive target for the development of novel anti-amebic chemotherapies. Epigenetic gene silencing of PanK resulted in a significant reduction of PanK activity, intracellular CoA concentrations, and growth retardation in vitro, reinforcing the importance of this gene in E. histolytica. Furthermore, we screened the Kitasato Natural Products Library for inhibitors of recombinant EhPanK, and identified 14 such compounds. One compound demonstrated moderate inhibition of PanK activity and cell growth at a low concentration, as well as differential toxicity towards E. histolytica and human cells.

1. Introduction

Coenzyme A (CoA) is an essential cofactor in all living organisms as an acyl group carrier and carbonyl-activating group involved in more than 100 cellular reactions (Begley et al., 2001); it is estimated to be a cofactor used in 9% of identified enzymatic reactions (Strauss, 2010). CoA biosynthesis is considered to be an essential and universal pathway of the majority of prokaryotes and eukaryotes (Leonardi et al., 2005b). In general, CoA participates in fatty acid metabolism, the tricarboxylic acid cycle and numerous other intermediary metabolic reactions (Abiko, 1975). CoA is synthesized from pantothenate (vitamin B₅), cysteine, and ATP (Jackowski, 1996; Leonardi et al., 2005b). Most of the eukaryotes are unable to synthesize pantothenic acid and thus rely on an external supply.

Entamoeba histolytica is the protozoan agent responsible for human amebiasis, an infectious disease causing dysentery and amebic liver abscesses, responsible for 100,000 deaths annually throughout the world. It represents the third most common parasitic cause of death, after malaria and schistosomiasis (Stanley, 2003; Ali and Nozaki, 2007; Ralston and Petri, 2011). The elaborate pathogenesis of this parasite is well documented (Espinosa-Cantellano and Martínez-Palomo, 2000; Nozaki and Bhattacharya, 2015). Metronidazole has, for decades, been the most effective drug in the treatment of amebiasis despite its known side effects and low efficacy against asymptomatic cyst carriers. Moreover, resistance, virulence and host immune response to metronidazole treatment in amebiasis have been reported in some countries (Griffin, 1973; Pittman and Pittmann, 1974; Johnson, 1993; Koch et al., 1997; Ali and Nozaki, 2007). The molecular target of metronidazole has been well described as a key metabolic enzyme, pyrurate: ferredoxin oxidoreductase, which is involved in acetyl CoA
production from pyruvate as part of central energy metabolism. Identification and characterization of novel drug targets unique to E. histolytica are therefore needed to design better therapeutics against amebiasis.

Here we investigate the CoA biosynthetic pathway of E. histolytica. We identified four enzymes, including one bifunctional enzyme, involved in this pathway. We further characterized one of these enzymes, pantothenate kinase (PanK, EC 2.7.1.33), with biochemical and reverse genetic approaches. Moreover, we identified E. histolytica PanK inhibitors by screening the Kitasato Natural Products Laboratory against EhPanK recombinant enzyme. Taken together, we demonstrate that the CoA biosynthetic pathway, in general, and PanK, specifically, represents a rational and novel drug target against amebiasis.

2. Materials and methods

2.1. Organisms, cultivation, and chemicals

Trophozoites of E. histolytica clonal strains HM-1: IMSS cl 6 and G3 (Bracha et al., 2006) were maintained axenically in Diamond’s Bl-S-33 medium at 35.5 °C as described previously (Diamond et al., 1978). Trophozoites were continuously maintained in mid-log phase after inoculation of one-thirtieth to one-twelfth of the total culture volume. Escherichia coli BL21 (DE3) strain was obtained from Invitrogen (Carlsbad, CA, USA). Magnesium-free ATP was procured from DiscoverX (Fremont, CA, USA). Ni²⁺-NTA agarose was procured from Ni²⁺-NTA agarose (Carlsbad, CA, USA). Magnesium-free ATP was procured from DiscoverX (Fremont, CA, USA). Ni²⁺-NTA agarose was procured from Ni²⁺-NTA agarose (Carlsbad, CA, USA).

2.2. Production of PanK gene-silenced strain

In order to construct a plasmid for epigenetic gene silencing of E. histolytica (Bracha et al., 2006; Zhang et al., 2011) PanK (EhPanK), a fragment corresponding to a 430 bp 5′ open reading frame of EhPanK gene was amplified by PCR from cDNA using the following primer set (sense primer, 5′-CACAGGCTCATGTCTCAACCCATCCCATTCTC-3′ and antisense primer, 5′-AATGAGCTCTGAGATTCACATCCCATTAA-3′). These oligonucleotides contained StuI and SacI restriction sites (shown in bold). The amplified product was digested with Stul and SacI, and ligated into the Stul and SacI double digested psAP2-Gunna construct (Husain et al., 2011) to synthesize a EhPanK gene silencing plasmid. The G3 strain trophozoites were transformed with an empty vector as a control and the silencing plasmid was transfected by liposome-mediated transfection as previously described (Nozaki et al., 1999). Transformants were initially selected in the presence of 1 μg/ml geneticin gradually increased to 10 μg/ml.

2.3. Reverse transcriptase PCR

RNA was extracted from approximately 1 × 10⁶ trophozoites of EhPanK gene silenced (PanK gs) and control transfected strains using TRIzol reagent (Ambion, Life Technologies) as previously described (Chomczynski and Mackey, 1995). DNase treatment was performed using DNase I (Invitrogen) to exclude genomic DNA. RNA quantity was determined by absorbance at 260 nm with a NanoDrop ND-1000 UV–Vis spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Approximately one μg total RNA was used for cDNA synthesis using First-stand cDNA Synthesis (Superscript III, Invitrogen) with reverse transcriptase and oligo (dt) primers according to manufacturer’s instructions. The cDNA product was diluted 10-fold and PCR reactions were carried out in 50 μl, using the primer pair (Sense primer, 5′-ATGTCTCAACCCATCCCATTCTC-3′ and antisense primer, 5′-TTACATTAGTGCTCTCTCATACTC-3′). The PCR conditions were: 98 °C, 10 s; 55 °C, 1 min; and 72 °C, 1 min; 20–25 cycles. The PCR products obtained were resolved by agarose gel electrophoresis.

2.4. Quantitative real-time (qRT) PCR

Relative levels of steady-state mRNA of the following genes were measured using qRT-PCR: PanK (EHI_183060), bifunctional phosphopantothe- nate-cysteine ligase/decarboxylase (PPCS-PDPDC, EHI_164490), phosphopantotheine adenyltransferase (PPAT, EHI_006680), dephospho CoA kinase 1 and 2 (DPCK1, EHI_040840; and DPCK2, EHI_155780), and RNA polymerase II gene (EHI_056690) as a reference gene. Each 20 μl reaction contained 10 μl 2X Fast SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA). 0.6 μl each of 10 μM sense and antisense primers, 5 μl 10X diluted cDNA, and nuclease-free water. PCR was performed using the StepOne Plus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) with the following cycling conditions: enzyme activation at 95 °C for 20 s, followed by 40 cycles of denaturation at 95 °C for 3 s and annealing-extension at 60 °C for 30 s. All reactions were carried out in triplicate, including cDNA-minus controls. The amount of the steady-state mRNA of each target gene was determined by the ΔΔCt method with RNA polymerase II as a reference gene (Livak and Schmittgen, 2001). The mRNA expression level of each gene in the transformant was expressed relative to that in the control transfected with psAP2.

2.5. Production of whole lysates from E. histolytica trophozoites

Approximately 1 × 10⁶ trophozoites were harvested 48 h after initiation of culture and washed with 2% glucose in 1X phosphate buffer saline (PBS) three times. Cells were counted and resuspended in 500 μl homogenization buffer (50 mM Tris-HCl, pH 7.5, 250 mM sucrose, 50 mM NaCl) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) and 0.5 mg/ml E-64 (Peptide Institute, Osaka, Japan). Cells were disrupted mechanically by a Dounce homogenizer and kept on ice for 30 min with intermittent vortexing followed by centrifugation at 500 × g for 30 min at 4 °C for removing the insoluble cellular debris. The supernatant, representing total cell lysate, was carefully collected. Protein concentrations were spectrophotometrically determined by the Bradford method using bovine serum albumin as a standard as previously described (Bradford, 1976).

2.6. Enzyme assays and quantitation of CoA in cell lysates

PanK and DPCK activities in the cell lysate were measured with coupled assays using ADP Hunter Plus Assay kit (DiscoverX, US) according to the manufacturer’s instructions. Briefly, fluorescence intensities were continuously measured to estimate the formation of resorufin at 37 °C by excitation at 530 nm and emission at 590 nm in a 25 μl reaction mixture [10 mM MgCl₂, 15 mM HEPES, 20 mM NaCl, 1 mM EGTA, 0.02% tween 20, 0.1 mg/ml β-globulin, 2 mM pantothe- nate or 2 mM dephospho CoA for PanK or DPCK, respectively, 0.1 mM ATP, 2 μl of cell lysate (~5 μg protein)]. Kinetic data were estimated by curve fitting with the Michaelis–Menten equation using GraphPad Prism (GraphPad Software Inc., San Diego, USA). This experiment was repeated three times in triplicate with proteins isolated from two independent extractions, and kinetic values are presented as the means ± S.E. for three independent kinetic assays.

Concentrations of CoA in the cell lysate were measured using the CoA assay kit (BioVision, CA, USA) according to manufacturer’s instructions. CoA at 0.05–1 nmol was used to produce a standard curve to determine the amounts of CoA in lysates. Experiment was conducted in triplicate, and repeated three times on three different days.

2.7. Monitoring of growth kinetics

Trophozoite cultures were continuously maintained in mid-log phase as described previously, and placed on ice for 5 min to detach
cells from the glass surface. Cells were collected by centrifugation at 500 × g for 5 min at room temperature. After discarding the spent medium, the pellet was re-suspended in 1 mL of BI-S-33 medium. Cell densities were estimated on a haemocytometer. Approximately 10,000 trophozoites were inoculated in 6 mL fresh BI-S-33 medium. Cultures were examined every 24 h for 5 days.

2.8. Genome-wide survey of enzymes involved in CoA biosynthesis in the E. histolytica genome

Putative genes encoding PanK, PPCS-PPCDC, PPAT, and DPCK were identified in the genome of HM-1:IMSS in the E. histolytica genome database (AmoebaDB, http://amoebadb.org/amoeba/) using the blastp online search tool (protein-protein BLAST). Human or bacterial orthologs (Human PanK1a/NP_683878.1, E. coli bifunctional CoaBC/ WP_089667520.1, Human bifunctional COASTY/AAL50813.1) retrieved from non-redundant protein sequences (nr) database of National Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/) were used as query sequences. Pathway analysis was conducted using Kyoto Encyclopedia of Genes and Genomes database (KEGG, https://www.genome.jp/kegg/). The steady-state mRNA level of each gene in the trophozoite stage was examined using our previous array data as an independent experiment in both HM1: IMSS cDNA (Penuliar et al., 2012, 2015) and G3 strains (Nakada-Tsukui et al., 2012; Furukawa et al., 2012, 2013). Then using Entamoeba invadens orthologs, we compared the mRNA expression levels of these genes during various timepoints during the encystation stage (De Cádiz et al., 2013).

2.9. Phylogenetic analysis of PanK

Putative orthologs of PanK from a variety of organisms were retrieved by a blastp search against each taxonomic group as shown in Table S1. In each blastp analysis, a list of selected sequences was made with an E-value less than 1 × 10^-10 in pairwise alignments with EhPanK. Based on the lists for all taxonomic groups in Table S1, we selected 81 sequences as a final data set. The Muscle program (Edgar, 2004) in SeaView software package version 4.6.1 (Gouy et al., 2010) was used for sequence alignment. Then 145 unambiguously aligned positions were selected by manual inspection and used for phylogenetic analyses.

The phylogenetic data matrices were subjected to analysis with the IQTREE program (Nguyen et al., 2015) to select appropriate models for amino acid sequence evolution. The LG + I + G4 model was found to be the best for analysis. Maximum likelihood (ML) analysis implemented in the RAxML program version 7.2.6 (Stamatakis, 2006) was used to infer the ML tree by applying LG + I + G4 model. In the bootstrap analysis, heuristic tree search was performed with a rapid bootstrap algorithm option (-f) for 100 bootstrap replicates. Bootstrap proportion (BP) values greater than 50 were indicated on the corresponding internal branches of the ML tree drawn with FigTree program Version 1.4.2 (http://tree.bio.ed.ac.uk/software/figtree/).

2.10. Production of E. histolytica transformant line to express Myc-tagged PanK

The EhPanK gene was amplified from cDNA using Ex Taq DNA polymerase (Takara) using the following primer set (sense primer, 5'-GCCGCCGATGGTCCTCAACATCCACTTTCCCATC-3' and antisense, 5'-GGCTC GAG TTCACTAGTTCTTCTCAGCTGCT-3'), restriction sites are indicated in bold. An amplified fragment was ligated into Smal and XhoI double digested pEhEx-Myc expression vector (Nakada-Tsukui et al., 2012) to produce pEhExMyc-PanK. The plasmid was introduced into trophozoites of E. histolytica HM-1:IMSS c6 (Diamond et al., 1978) by liposome-mediated transfection (Nozaki et al., 1999). Transformants were selected and maintained as described previously.

2.11. Cell fractionation and immunoblot analysis

Trophozoites of the amoeba transformant expressing Myc-EhPanK and the mock transformant, transfected with pEhEx-Myc, were washed three times with PBS containing 2% glucose. After resuspension in homogenization buffer (50 mM Tris-HCl, pH 7.5, 250 mM sucrose, 50 mM NaCl and 0.5 mg/mL E-64 protease inhibitor), cells were disrupted mechanically by a Dounce homogenizer on the ice, centrifuged at 500 × g for 5 min, and the supernatant was collected to remove unbroken cells. The supernatant fraction was centrifuged at 5000 × g for 10 min to isolate pellet and supernatant fractions. The 5000 × g supernatant fraction was further centrifuged at 100,000 × g for 60 min to produce a 100,000 × g supernatant and pellet fractions. The pellets at each step were further washed twice with homogenization buffer and re-centrifuged at 100,000 × g for 10 min to minimize carryover. Immunoblot analysis was performed using the fractions and anti-Myc mouse monoclonal antibody. Anti-CPBF1 (cysteine protease binding family protein 1) and anti-CS1 (cysteine synthase 1) rabbit antisera were used as organelle membrane and cytosolic markers, respectively.

2.12. Production of EhPanK recombinant protein

The plasmid was constructed as previously described (Sambrook and Russell, 2001). DNA fragment was amplified from E. histolytica cDNA. Primers used were sense, 5'-GCCGCCGATGGTCCTCAACATCCACTTTCCCATC-3' and antisense, 5'-GGCTC GAG TTCACTAGTTCTTCTCAGCTGCT-3'. Bold letters indicate BamHI and SalI restriction sites. PCR was performed with primeSTAR HS DNA polymerase (Takara) and the following parameters: initial incubation at 98 °C for 30 s; followed by the 30 cycles of denaturation at 98 °C for 10 s; annealing at 55 °C for 30 s; and elongation at 72 °C for 1 min; and a final extension at 72 °C for 7 min. The PCR fragment was digested with BamHI and SalI, purified with Wizard® SV Gel and PCR Clean-up System (Promega). The fragment was cloned into BamHI and SalI double digested pCOLDI™ histidine-tag vector (Takara) to finally produce pCOLD1-EhPanK. The nucleotide sequence of the engineered plasmid was verified by sequencing.

pCOLD1-EhPanK was introduced into E. coli BL21(DE3) cells via heat shock at 42 °C for 1 min. E. coli BL21 (DE3) harboring pCOLD1-EhPanK was grown at 37 °C in 100 mL of Luria Bertani medium (Invitrogen) in the presence of 100 μg/mL ampicillin (Nacalai Tesque). The overnight culture was used to inoculate 500 mL of fresh medium, and the culture was further continued at 37 °C with shaking at 180 rpm. When A600 absorbance reached 0.8, then 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG) was added, and cultivation was continued for another 24 h at 15 °C. E. coli cells from the induced culture were harvested by centrifugation at 5000 × g for 20 min at 4 °C. The cell pellet was washed with PBS, pH 7.4, re-suspended in 20 mL of the lysis buffer (50 mM Tris HCl, pH 8.0, 300 mM NaCl, and 10 mM imidazole) containing 0.1% Triton X-100 (v/v), 100 μg/mL lysozyme, and 1 mM PMSF, and incubated at room temperature for 30 min. Then the mixture was sonicated on ice and centrifuged at 25,000 × g for 15 min at 4 °C. The supernatant was mixed with 1.2 L of 50% Ni2+-NTA His-bind slurry, incubated for 1 h at 4 °C with mild shaking. The recombinant enzyme-bound resin in a column was washed three times with buffer A (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, and 0.1% Triton X-100, v/v) containing 10–50 mM of imidazole. Bound protein was eluted with buffer A containing 100–300 mM imidazole. After the integrity and the purity of recombinant protein were confirmed with 12% SDS-PAGE analysis, followed by Coomassie Brilliant Blue staining, the sample was dialyzed against a 300-fold volume of 50 mM Tris-HCl, 150 mM NaCl, pH 8.0 containing 10% glycerol (v/v) and the Complete Mini protease.
2.14. Measurement of anti-amebic activity of EhPanK inhibitor compounds

Approximately $1 \times 10^4$ trophozoites of *E. histolytica* clonal strain HM-1:IMSS cl6 in 200 μl of BI-S-33 medium were dispensed into each well of a 96-well plate and incubated at 35.5°C for 2 h. Medium was then removed and replaced with 200 μl of BI-S-33 medium that contained various concentrations of each compound. The final concentrations of test compounds are 50–600 μM for cephaloridine, hygromycin A, erythromycin A, and fluoresceamine; 5–200 μM for kasugamycin, garamycin, rosamicin, streptomycin, tirandamycin A, neomycin, and teicoplanin; 0.1–10 μM for O-methylanamycin A, echinomycin, and trichostatin. The plate was incubated under anaerobic conditions at 35.5°C for 48 h. After the medium was removed, 100 μl of pre-warmed Opti-MEM I (Life Technologies, Grand Islands, NY, USA) was added. The viability of trophozoites was estimated by measuring absorbance at 450 nm by SpectraMax® Paradigm® (Molecular Devices, CA, USA). Metronidazole was used as positive control at final concentrations of 0.1–10 μM and 0.5% DMSO as negative control. Each assay was performed in triplicate. IC$_{50}$ values were calculated by least squares curve fitting of the dose inhibition curves using GraphPad Prism (GraphPad Software Inc., San Diego, USA).

2.15. Evaluation of cytotoxicity against MRC-5 cells

Human fibroblast cells, MRC-5, were cultured on 96-well flat bottom plates at a density of $1.5 \times 10^4$ cells/well with 100 μl of MEM medium (Life Technologie) containing 10% fetal bovine serum (Hanaresco Bio, Tokyo, Japan) and 1% penicillin-streptomycyin (Life Technologies). Cells were incubated at 37°C with 5% CO$_2$ for 48 h. Approximately 100 μl of MEM medium containing 5 μl of each compound dissolved in 50% DMSO in water were added to each well. After the plates were incubated for 48 h, approximately 10 μl of WST-8 (Dojindo, Kumamoto, Japan) was added to each well and the plate was incubated at 37°C with 5% CO$_2$ for 2 h. The absorbance was measured at 450 nm by spectrophotometer (SH-9000Lab, Corona Electric, Ibaraki, Japan). Growth of MRC-5 cells was measured in duplicate. Staurosporine (Kitasato Natural Products Library) was used as a positive control.
positive (cytotoxic) control in a concentration range of 0.5 pM to 0.1 nM IC₅₀ values were calculated as described previously.

3. Results

3.1. Identification of four enzymes involved in CoA biosynthesis in E. histolytica

We identified all putative genes involved in CoA biosynthesis in the reference genome of E. histolytica: HM-1:IMSS (Fig. 1). Four genes encoding sequential pathway enzymes were identified: pantothenate kinase (EC 2.7.1.33, PanK), bifunctional phosphopantothenate-cysteine ligase/decarboxylase (EC 6.3.2.5/EC 4.1.1.36), phosphopantetheine adenylyltransferase (EC 2.7.7.3), and dephospho CoA kinase (EC 2.7.1.24). We identified a single putative PanK gene in each strain (e.g., EHI_183060 in HM-1:IMSS and EH7A_012650 in HM-1:IMSS-A) in Amoeba Genomics Resources database, Amoebadb8 (http://amoebadb.org). The nucleotide sequences of the genes in different strains are 100% identical. Therefore, E. histolytica seems to have only one PanK gene.

Our previous transcriptome data verified that all four genes are expressed at low to moderate levels (Fig. S1A). The level of mRNA expression relative to RNA polymerase for PanK, PPCS-PPCDC, PPAT, DPPCK1, and DPPCK2 in trophozoites of the E. histolytica clonal strain HM1: IMSS c6 (Penuliar et al., 2015, 2012) and G3 (Nakada-Tsukui et al., 2012; Purukawa et al., 2012, 2013) strain were 1.2–1.8, 0.5–0.6, 0.3–0.4, 0.04–0.05 and 0.3–0.4, respectively. In this research, we describe biochemical and genetic characterization of PanK; investigation of other enzymes involved in CoA biosynthesis will be described elsewhere. Our previous transcriptomic analysis of E. invadens (De Cádiz et al., 2013), as a model for encystation (Donaldson et al., 1975; Kojimoto et al., 2001; Stanley, 2003; Chia et al., 2009), showed that genes encoding these four enzymes were expressed during encystation, but the expression profiles of individual enzymes largely differed (Fig. S1B). The expression profiles of PPCS-PPCDC and DPPCK1 were quite peculiar with expression peaking at certain time points (2 h and 24 h, respectively); this subject was, however, not investigated as part of this study.

3.2. Features of EhPanK and its encoded protein

The 1219-bp E. histolytica PanK gene contains two small introns, and is predicted to encode a 403 a.a. polypeptide with a molecular mass of 45.2 kDa and a pI value of 5.2. EhPanK showed 99, 96, 83, and 70% sequence identity to PanK from E. nuttalli, E. dispar, E. moshkovskii, and E. invadens, respectively. In general, PanK is classified into three groups, type I through III, as determined by primary sequence analysis and kinetic properties (Song and Jackowski, 1993; Rock et al., 2002; Yang et al., 2006). E. histolytica PanK is classified as PanK type II, and shows a low level (~35%) of positional identity to the A. thaliana and human orthologs, both of which also belong to type II (Fig. S2 and S3). When compared to human PanK, Entamoeba PanK shows the highest similarity to human PanK4 (35%), whereas similarity to other human PanK iso-types (PanK1a, PanK1b, PanK2, and PanK3) is ~32%. All amino acid residues were inferred to be involved in pantothenate and ATP catalysis and substrate binding include the typical ATP-binding motif have been reported in human PanK1 and PanK3 (Bum et al., 2007). Some conserved glycine residues in the ATP binding motif (Gly19 and Gly143) in human PanK3; Gly99 and Gly151 in E. histolytica) are indispensable for activity. Mutations of this amino acid have been demonstrated to abolish enzymatic activity because ATP is no longer able to properly bind (Bum et al., 2007). Furthermore, it is understood that phosphorylation is proceeded by an ordered sequential mechanism, with ATP binding preceding pantothenate binding (Leondard et al., 2005a).

3.3. Phylogenetic analysis of EhPanK

We determined the phylogenetic relationship between 81 putative PanK orthologs collected from bacteria and eukaryotes (Table S1, Fig. S2). The majority of eukaryotes possess the PanK gene. Mammals (Oipithokonta) and land plants (Viridiplantae) apparently possess two or more two genes. For instance, four PanK genes were identified from Homo sapiens, PanK1a and PanK1b (Rock et al., 2002), PanK2 (annotated as a mitochondrial precursor protein) (Hörtnagel et al., 2003; Kotzbauer et al., 2005), and PanK3 (Zhang et al., 2005). Archaea and most bacterial groups do not possess PanK homologs that show similarity to EhPanK with the E-value less than 10⁻¹⁰. PanK homologs were identified, however in Firmicutes, specifically Bacilli. During sequence alignment, only the ‘fumble’ domain (PFAM:PF003630) could be aligned among all 81 sequences, although insertions and deletions were needed for proper alignment due to a high degree of divergence. PanKs from Euglenozoa have an ~1000-a.a. long N-terminal extension, which contains an exonuclease-endonuclease-phosphatase (EEP) domain in the 300 a.a.-long N-terminal region and a 550 a.a.-long adenylyl forming (AF) domain. Some of PanK from Viridiplantae have a 300 a.a.-long C-terminal extension, annotated as DUFB9 (Domain of Unknown Function 89) (Huang et al., 2016). PanK from other organisms including the genus Entamoeba basically contain only a ‘fumble’ domain; neither the EEP/AF nor DUFB9 domain is present in PanK from other organisms except that some possess an N-terminal extension that appears to be an organelle targeting sequence.

Based on 145 aligned positions from the ‘fumble’ domain, an optimal ML tree was created with bootstrap proportion (BP) support values (Fig. S2). Eukaryotes and Firmicutes were separated clearly with a 100% BP support value. The Eukaryota clade had monophyly of several taxonomic groups reconstructed, but BP values were generally low except for those of Viridiplantae monophyly (88%) and Haptophyceae monophyly (97%). Four Entamoeba species are monophyletic with 100% BP support, and the Entamoeba clade shares a sister group position to the clade of Euglenozoa. However, since BP support values for deep branching patterns were very low, monophyly of Amoebozoa including the Entamoeba clade cannot be ruled out. Although this analysis could not precisely infer the phylogenetic position of the Entamoeba PanK, it is apparently of an eukaryotic origin.

3.4. Expression and purification of recombinant PanK

A soluble EhPanK recombinant protein with a 2.6 kDa histidine tag at the amino terminus was successfully produced using the pCold I E. coli expression system and purified to homogeneity (> 95% as evaluated with Coomassie Brilliant Blue stained SDS-PAGE gel) (Fig. S4A, Table S2). Immunoblot analysis of the purified recombinant protein using His-Tag antibody confirmed the absence of truncation (Fig. S4B). The molecular mass of the purified protein under reducing conditions was consistent with the predicted molecular mass 45.2 kDa excluding the histidine tag. The specific activity of the purified enzyme was estimated to be 1.5 μmol/min/mg when assayed under the standard conditions described in the "Materials and methods" section. EhPanK is robust and catalytically active in broad pH range with maximum activity obtained at pH 6 and 37 °C (Fig. S5A).

3.5. Kinetic properties and phosphoryl donor specificities of EhPanK, and effects of metal ions on EhPanK

Table 1 summarizes the apparent Kₘ, Vₘₐₓ, and Kₗₐₜ values for EhPanK using pantothenate and ATP as substrates. EhPanK exhibited hyperbolic saturation kinetics when assayed over the substrate range of 4–256 μM for pantothenate in the presence of 25–100 μM ATP (Fig. S5B) and 1–100 μM ATP in the presence of 8–128 μM pantothenate (Fig. S5C). The apparent Kₘ value for pantothenate at saturating ATP concentrations was 53.2 ± 7.1 μM, and the Kₘ value for ATP at saturating conditions.
Table 1

Kinetic parameters of E. histolytica pantotheenate kinase.

| Substrate                  | $K_m$ (μM) | $V_{max}$ (μmole/min/mg) | $K_m$ (μM) | $K_{cat}/K_m$ (min⁻¹ μmole⁻¹) |
|----------------------------|------------|--------------------------|------------|-------------------------------|
| Pantothenate               | 53.2 ± 7.1 | 2.79 ± 0.1               | 126.8 ± 4.5 | 2.38 ± 0.08                  |
| ATP                        | 41.4 ± 3.9 | 2.84 ± 0.2               | 129.1 ± 9.2 | 3.11 ± 0.22                  |

Mean ± SEM of three replicates are shown.

Table 2

Phosphoryl donor specificity of E. histolytica pantotheenate kinase.

| Phosphoryl donor | Relative activity (%) | Phosphoryl donor | Relative activity (%) |
|------------------|-----------------------|------------------|-----------------------|
| ATP              | 100.0 ± 4.1           | CTP              | 1.4 ± 0.2             |
| GTP              | 78.8 ± 4.9            | Metaphosphate    | ND                    |
| dATP             | 19.3 ± 4.3            | Hexametaphosphate| ND                    |
| Tripolyphosphate | 16.9 ± 0.8            | Trimetaphosphate | ND                    |
| UTP              | 16.6 ± 1.2            | Glucose-6-phosphate| ND                   |
| Polyphosphate    | 16.2 ± 2.5            | Phosphoenolpyruvate| ND                   |
| TTP              | 5.4 ± 1.9             | None             | ND                    |

Assays were performed as described in Materials and methods, in the presence of 100 mM NaCl, 10 mM MgCl₂, 1 mM EGTA, 0.02% Tween-20, 0.1 mg/mL β-γ-globulins and 0.2 mM pantothenate. Reactions were conducted at 37 °C at pH 6. The activity is shown in percentage (%) relative to that toward ATP. ND, not detected.

Table 3

Effect of metal ions on the activity of E. histolytica pantotheenate kinase.

| Metal      | Relative activity (%) |
|------------|-----------------------|
| MgCl₂      | 100.0 ± 0.0           |
| CuCl₂      | 84.3 ± 4.7            |
| MnCl₂      | 83.2 ± 2.0            |
| CoCl₂      | 74.2 ± 6.1            |
| FeCl₂      | 72.8 ± 1.7            |
| LiCl₂      | 34.5 ± 1.8            |
| CaCl₂      | 17.0 ± 3.0            |
| ZnCl₂      | 3.9 ± 0.7             |
| NiCl₂      | ND                    |
| NaCl       | ND                    |
| KCl        | ND                    |
| None       | ND                    |

Assays were performed as described in Materials and methods, in the presence of 100 mM ATP, 15 mM HEPES, 20 mM NaCl, 1 mM EGTA, 0.02% Tween-20, 0.1 mg/mL β-γ-globulins and 0.2 mM pantothenate. Reactions were conducted at 37 °C at pH 6.0. The activity is shown in percentage (%) relative to that toward MgCl₂, ND, not detected.

Mean ± SEM of three replicates are shown.

3.6. Regulation of EhPanK by CoA, acetyl CoA, and malonyl CoA

PanK from other organisms was reported to be negatively regulated by allosteric inhibition with CoA, acetyl CoA, and malonyl CoA (Calder et al., 1999; Takagi et al., 2010; Vallari et al., 1987). Similarly, EhPanK showed an absolute requirement for a free bivalent metal co-factor, with Mg²⁺ as the preferred cation (Table 3).

3.9. Identification of EhPanK inhibitors from Kitasato Natural Products Library

Based on the significant biological role of EhPanK, inhibitors of this enzyme should be considered to possess properties needed for novel anti-amoebic agents. Therefore, we conducted enzyme-based screening of the Kitasato Natural Products Library composed of 244 structurally elucidated compounds using recombinant EhPanK to identify potential PanK inhibitors. We identified 14 compounds (Table 5) that demonstrated an IC₅₀ value of < 400 μM (Table 4, Fig. S8). Among these compounds, Teicoplanin had the best inhibitory activity against EhPanK with an IC₅₀ value of 26.3 ± 2.6 μM. All EhPanK inhibitors also inhibited E. histolytica trophozoites although the IC₅₀ values of most of the identified EhPanK inhibitors were high. Six compounds, O-methylanaomycin A, Echinomycin, Tirandamycin A, Neomycin, Trichostatin, and Teicoplanin, showed the IC₅₀ values of < 20 μM against E. histolytica trophozoites, but the IC₅₀ values of O-methylanaomycin A, Echinomycin, Tirandamycin A, Neomycin, and Trichostatin against E. histolytica trophozoites were lower than their IC₅₀ values against EhPanK activity, suggesting that the target of these compounds for growth inhibition are unlikely to be through PanK inhibition. In contrast, Teicoplanin demonstrated comparable IC₅₀ values against PanK activity and E. histolytica growth (Table 5).

3.7. Cellular localization of EhPanK

To examine the localization of EhPanK, we performed fractionation and immunoblot analysis of PanK using E. histolytica transformant-expressing Myc-tagged EhPanK. We demonstrated that EhPanK is exclusively present in the 100,000 × g supernatant fraction corresponding the cytosol (Fig. S6).

3.8. Effects of EhPanK gene silencing on growth, cellular CoA levels, and gene expression of the CoA biosynthetic pathway

To investigate the physiological importance and essentiality of PanK in E. histolytica, we created and examined an E. histolytica strain where EhPanK was silenced by antisense small RNA-mediated transcriptional gene silencing (Mirelman et al., 2008); EhPanK gene expression was successfully silenced (Fig. 4A). The level of silencing was estimated to be approximately 85% by qRT-PCR measurement. Interestingly, the steady-state transcript of the genes encoding other enzymes involved in CoA biosynthesis were up-regulated 1.2 ± 0.03, 2.1 ± 0.2, 3 ± 0.1, and 5.2 ± 1.0-fold for PPCS-PPCDC, PPAT, DPCK1, and DPCK2, respectively (Fig. 4B).

In order to determine whether the protein level also increased, we measured PanK and DPCK activity in cell lysates. PanK activity decreased by approximately 81% in the EhPanK-silenced strain compared to the control. In contrast, DPCK activity increased 2.1-fold (Fig. 4C). CoA concentration decreased by approximately 40% in EhPanK-silenced strain compared to the control (Fig. 4D). Growth kinetic analysis also showed that in EhPanK-silenced strain showed remarkable growth retardation as the cell density of EhPanK-silenced strain decreased to approximately 30–52% of the control at 48–96 h, respectively (Fig. 4E, Fig. S7A, Fig. S7B).
4. Discussion

4.1. Identification of CoA biosynthesis as rational drug target

CoA is an essential and ubiquitous cofactor functioning as an acyl carrier as well as a carbonyl activating group for many metabolic reactions. In the present study, we identified four enzymes that are involved in CoA synthesis in *E. histolytica* (Fig. 1) and characterized the first rate-limiting enzyme in this process, PanK. We have provided evidence for the pivotal role of this enzyme in cell proliferation by gene silencing.

Since all genes involved in CoA biosynthesis are transcribed in all amoeba life cycle stages, this pathway is the good target not only for killing the pathogenic trophozoites but inhibiting stage conversion and thus amoeba transmission. The mechanism coordinating gene expression regulation among the five genes involved in *E. histolytica* CoA biosynthesis remains elusive. However, based on our previous transcriptomic analysis of *E. invadens*, a related reptilian amoeba species that also causes an invasive disease and has been used as a model system for *E. histolytica* (Donaldson et al., 1975; Kojimoto et al., 2001; Chia et al., 2009) during encystation (De Cádiz et al., 2013), we found that PanK is transcribed in both trophozoite and encystation life cycle stages at comparable levels, suggesting that PanK is required in both stages.

A *EhPanK* gene-silenced strain was successfully established, after producing a strain in which *EhPanK* gene expression was ~85% repressed. Four failed attempts to create of such a cell line (data not shown) suggest the essentiality of this gene. The low levels of EhPanK in our experiment can keep the cells viable, consistent with the previous publication in *Mycobacterium tuberculosis* PanK (Reddy et al., 2014). Interestingly, *EhPanK* gene silencing resulted in the simultaneous transcriptional up-regulation of genes for downstream CoA pathway enzymes. Remarkably, such genes, DPCK1 and DPCK2, were up-regulated 3- and 5-fold, respectively. This observation is similar to that in experimentation with *Plasmodium yoelii*, where other genes in the CoA biosynthetic pathway were up-regulated when *PanK2* gene was knocked out (Hart et al., 2016). Despite the apparent compensatory upregulation of downstream enzyme genes, CoA concentration was significantly reduced, which is most likely a direct cause of decreased ATP generation and retarded growth.

In order to validate EhPanK as the drug target, there should be notable biochemical, structural, and genetic differences in their human homologs. Such characteristics should, in theory, minimize toxic side effects of pharmacological inhibition of human enzymes via amebiasis chemotherapy. *E. histolytica* has one PanK enzyme whereas *Homo sapiens* has five PanK isoforms encoded by four genes. EhPanK is most closely related to human PanK4 with 35% amino acid identity, but phylogenetic analyses suggest a distant relationship between EhPanK and its human counterparts.

While PanK is indispensable for the optimal growth of *E. histolytica* trophozoites, but in some eukaryotes, including human, PanK was shown non-essential. It has been demonstrated that human cells have the ability to hydrolyze exogenous CoA to 4'-phosphopantetheine by eucaryote pyrophosphatase, and then incorporate 4'-phosphopantetheine and enzymatically convert it back to CoA by the bifunctional enzyme CoA synthase (Srinivasan et al., 2015). In *Plasmodium*, it was reported that PanK is nonessential in blood stage parasite development, but essential in the hepatic stage, as well as oocyst and sporozoite formation in the mosquito (Hart et al., 2016; Srivastava et al., 2016). In *M. tuberculosis*, CoA was proven to be an essential enzyme (Awasthy et al., 2010), but was also shown in vivo and in vitro studies to be a suboptimal target for antimycobacterial drug development because expression of CoA gene needs to be repressed to obtain sufficient cidal effects by inhibitors (Reddy et al., 2014). On the other hand, CoaBC, a bifunctional enzyme in the CoA biosynthesis, has been proven to be essential, but its suitability as drug target needs to be chemically validated in future (Evans et al., 2016). Inhibition of PanK in human cells may be tolerated, which also supports the premise that PanK is a reasonable chemotherapeutic target against pathogens for humans.

4.2. Hit discovery of EhPanK inhibitors

Historically, natural products, especially secondary metabolites, have provided various drugs against human diseases (Newman and Cragg, 2012). Our group has recently discovered several natural compounds from fungi and actinomycetes that inhibit cysteine synthase, an enzyme absent in humans and involved in *de novo* biosynthesis of L-cysteine (Mori et al., 2015). In this study, we identified 14 inhibitors of EhPanK; half of the inhibitors have sugar moieties, and some of them are aminoglycosides.
Teicoplanin showed moderate inhibitory activity with IC_{50} 26.3 ± 2.6 μM and inhibition of *E. histolytica* trophozoite growth (IC_{50} 15.1 ± 2.3 μM). Although Teicoplanin also demonstrated cytotoxicity to MRC-5 cells, preference towards *E. histolytica* cells was identified. Teicoplanin is a mixture of glycopeptide antibiotics used against Gram-positive bacteria including methicillin-resistant *Staphylococcus aureus*, with a mechanism of action inhibiting bacterial cell wall synthesis. Teicoplanin consists of the glycopeptide core, two carbohydrates (mannose and N-acetylglucosamine), and a side chain. The components of teicoplanin are classified by their side chain length and conformation; the major components are A2-1 through A2-5.

In conclusion, we have shown that pantothenate kinase and CoA biosynthesis are physiologically important for this parasite. We have also shown that potential EhPanK inhibitors were identified by screening the natural product library, suggesting that the enzyme can be a new target for the development of anti-amebic drugs.
Fig. 4. Analyses of EhPanK gene silenced strain. A) RT-PCR analysis of EhPanK gene transcript from *E. histolytica* transformants. “psAP” indicates control strain transfected with psAP-2-Gunma empty vector, and “PanK gs” indicates EhPanK gene silenced strain. B) Relative levels of gene transcripts encoding all four enzymes involved in CoA biosynthesis by qRT-PCR analysis in psAP and Pan Kgs transformants. qRT-PCR data were normalized against RNA polymerase II, and are shown in percentage relative to the transcript level of each gene in psAP control. C) PanK and DPCK activity in cell lysates of psAP and PanKgs transformants. D) CoA concentration in cell lysates. For B-D, data are shown in mean ± SEM of three biological replicates. Statistical comparison is made by Student’s t-test (*P < 0.05, **P < 0.01). E) Growth kinetic of *E. histolytica* transformants during 96 h incubation in BI-S-33 medium. Data are shown in mean ± SEM of three replicates. Data from one representative experiment of three conducted independently are shown. Statistical comparison is made by Student’s t-test (*P < 0.05, **P < 0.01).
Fig. 5. Structures of EhPanK inhibitors identified in this study.
Table 4

| Compound         | IC₅₀ (µM) |
|------------------|-----------|
| Cephaloridine    | 229.9 ± 10.1 |
| Kasugamycin      | 254.1 ± 4.7 |
| Gardimycin       | 49.2 ± 4.8  |
| Hygromycin A     | 193.7 ± 17.8 |
| O-methylmycoenymycin A | 283.8 ± 28.7 |
| Rosamycin        | 165.7 ± 2.0 |
| Streptomycin     | 154.4 ± 10.1 |
| Erythromycin A   | 131.3 ± 6.0 |
| Ethinomycin      | 77.8 ± 4.4  |
| Tirandamycin A   | 228.8 ± 3.4  |
| Neomycin         | 147.2 ± 6.8  |
| Fluorescamine    | 346.4 ± 14.7 |
| Trichostatin     | 309.9 ± 14.9 |
| Teicoplanin      | 26.3 ± 2.6   |

Mean ± SEM of three replicates are shown.

Table 5

| Compound                     | IC₅₀ (µM)    |
|------------------------------|-------------|
| E. histolytica trophozoite    |             |
| Cephaloridine                | 245.78 ± 34.92 |
| Kasugamycin                  | 66.16 ± 13.68  |
| Gardimycin                   | 34.36 ± 31.60  |
| Hygromycin A                 | 142.22 ± 16.34  |
| O-methylmycoenymycin A       | 1.68 ± 0.05    |
| Rosamycin                    | 56.34 ± 11.72  |
| Streptomycin                 | 77.53 ± 1.52   |
| Erythromycin A               | 155.88 ± 20.57  |
| Ethinomycin                  | 0.26 ± 0.04    |
| Tirandamycin A               | 13.71 ± 4.85   |
| Neomycin                     | 10.58 ± 1.12   |
| Fluorescamine                | 167.90 ± 20.07  |
| Trichostatin                 | 0.29 ± 0.04    |
| Teicoplanin                  | 15.08 ± 0.25   |
| Metronidazole                | 0.66 ± 0.05    |

Mean ± SEM of three replicates are shown.

Acknowledgements

We thank all members of Nozaki Lab, NIID, particularly, Kimiko Nakada-Tsukui, Yumiko Saito-Nakano, Takeshi Annoura, Herbert Santos, Yuki Hanadate, and Ratna Wahyun. We thank Russell Miller for proofreading of the manuscript. We also thank RISET-Pro Kemenristekdikti, the Ministry of Research, Technology, and Higher Education, Indonesia. This work was supported in part by a grant for Science and Technology Research Partnership for Sustainable Development from Japan Agency for Medical Research and Development (AMED) and Japan International Cooperation Agency (JICA), a grant for Research on Emerging and Re-emerging Infectious Diseases from AMED, Grants-in-Aid for Challenging Research (Exploratory) (17K19416), for Scientific Research (15H04406) and for Scientific Research on Innovative Areas (23117001, 23117005, 23390099) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT).

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.jipddr.2018.02.004.
Penuliar, G.M., Furukawa, A., Nakada-Tsukui, K., Husain, A., Sato, D., Nozaki, T., 2012. Transcriptional and functional analysis of trifluoromethionine resistance in Entamoeba histolytica. J. Antimicrob. Chemother. 67, 375–386. doi:10.1093/jac/dkr484.

Penuliar, G.M., Nakada-Tsukui, K., Nozaki, T., 2015. Phenotypic and transcriptional profiling in Entamoeba histolytica reveal costs to fitness and adaptive responses associated with metronidazole resistance. Front. Microbiol. 6. doi:10.3389/fmicb.2015.00354.

Pittman, F.E., Pittmann, J.C., 1974. Amebic liver abscess following metronidazole therapy for amebic colitis. Am. J. Trop. Med. Hyg. 23, 146–150.

Ralsot, K.S., Petri, W., 2011. The ways of a killer: how does Entamoeba histolytica elicit host cell death? Essays Biochem. 51, 193–210. http://dx.doi.org/10.1042/bsb051093.

Reddy, B.K.K., Landge, S., Ravishankar, S., Patil, V., Shinde, V., Tantry, S., Kale, M., Raichurkar, A., Menasankai, S., Mudgal, N.V., Ambady, A., Ghosh, A., Tundguru, R., Kaur, P., Singh, R., Kumar, N., Bharath, S., Sundaram, A., Bhat, J., Sambandamurthy, V.K., Bijerkled, C., Jones, T.A., Das, K., Bandodkar, B., Malalanarasimhan, K., Mukherjee, K., Ramachandran, V., 2014. Assessment of Mycobacterium tuberculosis pantothenate kinase vulnerability through target knock-down and mechanistically diverse inhibitors. Antimicrob. Agents Chemother. 58, 3312–3326. http://dx.doi.org/10.1128/AAC.00140-14.

Rock, C.O., Karim, M.A., Zhang, Y.M., Jackowski, S., 2002. The murine pantothenate kinase (Pank1) gene encodes two differentially regulated pantothenate kinase isoforms. Gene 291, 35–43. doi:10.1016/S0378-1119(02)00564-4.

Sambrook, J., Russell, D.W., 2001. Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Lab. Press. Cold Spring Harbor, NY, pp. 999.

Song, W.J., Jackowski, S., 1993. Cloning, sequencing, and expression of the pantothenate kinase (coa) gene of Entamoeba coli. [Erratum to document cited in CA119(7):64394q]. J. Bacteriol. 175, 2792.

Srivivasan, B., Barathashivil, M., van der Zwaag, M., Kanon, B., Colombelli, C., Lambrecht, R.A., Schaar, O., Nollen, E.A., Podgorsek, A., Kosec, G., Petkov, H., Haylick, S., Tiran, V., Reijngoud, D.J., Grzeschik, N.A., Sibon, O.C.M., 2015. Extracellular 4’-phosphopantetheine is a source for intracellular coenzyme A synthesis. Nat. Chem. Biol. 11, 784–792. http://dx.doi.org/10.1038/nchembio.1906.

Srivastava, A., Philip, N., Hughes, K.R., Georgiou, K., Creagh, J.J., Barrett, M.P., Czek, D.J., McConville, M.J., Waters, A.P., 2016. Stage-specific changes in Phasmodium metabolism required for differentiation and adaptation to different host and vector environments. PLoS Pathog. 12. http://dx.doi.org/10.1371/journal.ppat.1006094.

Stamatakis, A., 2006. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics 22, 2688–2690. http://dx.doi.org/10.1093/bioinformatics/btl446.

Stanley, S.L., 2003. Amebiasis. Lancet 361, 1025–1034. http://dx.doi.org/10.1016/S0140-6736(03)12830-9.

Straus, E., 2010. Coenzyme A biosynthesis and enzymology. In: Comprehensive Natural Products II Chemistry and Biology, pp. 351–410. http://dx.doi.org/10.1016/B978-080535382-8.00141-6.

Takagi, M., Tamaki, H., Miyamoto, Y., Leonardi, R., Hanada, S., Jackowski, S., Choban, S., 2010. Pantothenate kinase from the thermophilic archaeon Pyrodictium torridus. J. Bacteriol. 192, 233–241. http://dx.doi.org/10.1128/JB.00121-09.

Vallani, D.S., Jackowski, S., Rock, C.O., 1987. Regulation of pantothenate kinase by coenzyme A and its thiosters. J. Biol. Chem. 262, 2468–2471.

Yang, K., Eyobo, Y., Brand, L.A., Martyossyan, D., Tomchick, D., Straus, E., Zhang, H., 2006. Crystal structure of a type III pantothenate kinase: insight into the mechanism of an essential coenzyme A biosynthetic enzyme universally distributed in bacteria. J. Bacteriol. 188, 5532–5540. doi:10.1128/JB.00469-06.

Zhang, H., Alramini, H., Tran, V., Singh, U., 2011. Nucleus-localized antisense small RNAs for amebic colitis. Am. J. Trop. Med. Hyg. 23, 146–150.